Treogtres (HAE) patienter fik icatibant i to fase III- undersøgelser som behandling for et anfald i den kontrollerede fase, mens 118 patienter blev behandlet i den åbne fase.
Sixty three (HAE) patients received icatibant in two Phase III trials for treatment of an attack in the controlled phase and 118 patients were treated in the open label phase.